April 20, 2020 09:18 AM EDTUpdated 10:22 AM
R&D

Ex­elix­is lands PhI­II kid­ney can­cer win with Bris­tol My­ers in their hunt for $4 bil­lion

Jason Mast

Editor

Three months af­ter CEO Michael Mor­ris­sey ca­su­al­ly tossed a $4 bil­lion peak sales fig­ure for his com­pa­ny at the JP Mor­gan Health­care Con­fer­ence, Ex­elix­is is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times